Microbot Medical Inc. (NASDAQ:MBOT - Get Free Report) passed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $1.67 and traded as high as $2.67. Microbot Medical shares last traded at $2.54, with a volume of 1,310,034 shares traded.
Analyst Upgrades and Downgrades
Separately, HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of Microbot Medical in a research note on Thursday, April 10th.
View Our Latest Stock Analysis on MBOT
Microbot Medical Stock Performance
The stock has a market capitalization of $96.58 million, a PE ratio of -3.33 and a beta of 1.15. The business has a 50 day moving average of $2.16 and a two-hundred day moving average of $1.71.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last announced its earnings results on Wednesday, May 21st. The biotechnology company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.07. On average, equities analysts expect that Microbot Medical Inc. will post -0.71 EPS for the current fiscal year.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently made changes to their positions in the stock. Virtu Financial LLC acquired a new position in shares of Microbot Medical in the first quarter valued at about $42,000. Goldman Sachs Group Inc. purchased a new stake in Microbot Medical in the 1st quarter worth $57,000. Renaissance Technologies LLC purchased a new stake in shares of Microbot Medical during the fourth quarter worth about $118,000. Finally, Geode Capital Management LLC raised its holdings in shares of Microbot Medical by 7.9% during the fourth quarter. Geode Capital Management LLC now owns 142,659 shares of the biotechnology company's stock valued at $160,000 after acquiring an additional 10,442 shares during the last quarter. Hedge funds and other institutional investors own 16.30% of the company's stock.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
See Also
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
